Group off retinal research
 
The group started in 1992 with a clear vocation of developing applied research focused on retinal pathology, and with the main goal of providing solutions to the problems of patients and, as much as possible, of the market. At the beginning we analysed the composition and tolerance of the irrigation solutions used during vitrectomy, simultaneously we analysed different vitreous substitutes and developed experimental models of proliferative vitreoretinopathy (PVR), the most severe complication of retinal detachment. One of the most important landmarks of this group was the transfer of a silicone oil purification procedure to a Spanish enterprise that commercializes it.Back in 1997 we concluded the development of experimental models of PVR setting a porcine model, which is considered by many authors as a reference. Afterwards, started to use organotypic porcine and human retina cultures to study retinal degeneration process.In 2000 a new research line was started with the aim to identify patients at high risk of developing PVR after retinal detachment, at first individually, and later, since 2003, as multicentric projects based on the Red Tematica de Investigacion Cooperativa Sanitaria (Carlos III Institute of Health) called Retina 1, 2 and 4 projects. Some of the achievements of this research line are the identification of polymorphisms as PVR risk biomarkers. Currently, we are exploring the possibility of developing a diagnosis system that could be commercialized and clinically use.In addition, since 2001 a group led by Dr. Maribel López, has started to perform epidemiological research in diabetic retinopathy, and supporting tele-ophthalmology and imaging automatic analysis programs, with the collaboration of the Biomedical Engineering group of the University of Valladolid. Another important achievement of this research line is the screening of diabetic retinopathy in rural areas of Valladolid, and the experience of Telemedicine performed in Ávila and Zamora, that finished with a cost-effectiveness analysis in three health centres within Valladolid.Finally, since 2005, cell therapy research in retinal pathology has been performed, mainly focused on dry variant of age-related macular degeneration. This research line might allow the development of a clinical trial.
Purpose 
of group: 
The main goal of this research group is to give a response to the current unsolved problems in retinal pathology: to determine risk factors, investigate the pathogenesis and propose new therapeutic approaches.
Objectives: 
  • To create multidisciplinary clinical workgroups for the development of translational research projects.
  • To develop and improve experimental models (animal models, cellular and organotypic cultures) already set.
  • To investigate the pathogenesis of some retinal pathologies in order to identify new biomarkers and therapeutic targets.
  • To leader the organization of observational and experimental trials.
Research lines:  Develop lines of research:
1. Development of predictive models of proliferative vitreoretinopathy (PVR). Risk biomarkers:
Genetic risk factor identification associated to PVR development.
2. Advanced therapies:
Mesenchymal stem cell transplantation for the treatment of retinal degenerations and optic nerve diseases.
3. Biomedical research models:
Experimental models development for research in ophthalmology.
4. Retinal inflammation, wound-healing and cell death processes:
Molecular and cell changes analysis produced in inflammatory retinal diseases. Control of cell death processes.
5. Biomaterials for Retinal Pigment Epithelium (RPE) transplant:
Search of new materials for growing and maintaining RPE cells.
Services:  Services offered:
   
1.  Experimental models development:
The staff have a wide experience in experimental models development (animals, cellular and organotypic cultures) for research in ophthalmology.
2.  Drugs testing in models previously developed:
The models are considered appropriated for drugs tests.
3.  Predictive models for PVR:
Predictive risk formulas to identify patients at high risk of developing PVR after retinal detachment.
Pathologies:  Pathologies of study:
1.  Retinal detachment (RD):
Maintain cell viability and functionality after RD.
2.  Proliferative vitreoretinopathy:
Development of predictive risk formulas and identifying new therapeutics targets.
3.  Age-related macular degeneration:
Development of models and propose new therapies for dry AMD .
4.  Ischemic optic neuropathy:
Proposal of treatment with mesenchymal stem cells as neuroprotection agents.
Contact How to work with the group?
  Prof. Pastor Jimeno: pastor@ioba.med.uva.es.
Researchers:   
 

_

Achievements:  Major Achievements:
 
SIOBAL, AJL Ophthalmics S.A. Highly purified silicon oil for ocular surgery: Products transfered to enterprises.
LIOCAN, AJL Ophthalmics S.A. Intraocular lens for cataract surgery in dogs: Products transfered to enterprises.
Patents Nuestras patentes son:
Method of detection of patients at high risk for developing PVR: Method designed in order to be able to identify the risk to develop PVR in those patients that undergo retinal detachment surgery. Most precisely, the method consists on the detection of single-nucleotide polymorphisms (SNPs) or SNPs groups (haplotypes) that influence the development of this disease.
Pharmaceutic composition for treatment and/or prevention of degenerative retinal diseases: Composition based in stem cells and neurotrophic factors combination, which have an applicability in treatment and/or prevention of some retinal degenerations.
Projects Our five main projects are: (The other project documents)
1.  Ocular pathology network of ageing, visual quality and quality of life:
Carlos III National Institute of Health
2.  Retrospective multicentric study about the incidence of Proliferative Vitreoretinopathy (PVR) after Rhegmatogenous Retinal Detachment (RRD) in patients treated with Adalimumab:
Abbvie Laboratories S.A. 
3.  Evaluation of safety and efficacy of adipose-derived mesenchymal stem cells transplanted to subretinal space for age-related macular degeneration (AMD) treatment:
Research projects with enterprise collaboration and results transference. Junta de Castilla y León
4.  Cell therapy with stem cells for AMD:
Carlos III National Institute of Health
5.  Terapia celular con células madre para la degeneración macular asociada a la edad (DMAE):
General program for research projects support of the Junta de Castilla y León.
Partners Main partners and collaborators::
  Abbvie Laboratories Inc., IL, EE.UU.
AJL Ophthalmics, Vitoria, España
Aura Biosciences Inc., MA, EE.UU.
Novartis S.A., Barcelona, España
Paloma Pharmaceuticals, MA, EE.UU.
Xoma Corporation, CA, EE.UU.
Cadila Healthcare Limited., Ahmedabad, India.
ProRetina Therapeutics, Madrid, España
Aditya Jyot Eye Hospital Pvt. Ltd, Mumbai, India.
Nichi-In Centre for Regenerative Medicine (NCRM) the R&D unit of Nichi-In Bio Sciences Pvt Ltd., Chennai, India
SOM Biotech, Barcelona, España
Alcon Research & Development, Barcelona.
Work Plan
  STEP 1. Etiopathogenic studies in retinal diseases focused on new risk biomarkers and therapeutic targets.
STEP 2. Development and characterization of experimental models for biomedical research in ophthalmology and vision science that allow the study of several retinal diseases, and test new drugs.
STEP 3. Development of advanced therapies for the treatment of retinal pathologies.
Infrastructure Infrastructure and technical equipment highlights:
Ocular Pathology Laboratory  
Cultivation Cell Laboratory  
Molecular Biology Laboratory
 
Retina laboratory
 
Animal experimentation operating room
 
Activity codes  AT Codes: CNAE Codes: Unesco Codes:
A07 Biochemistry
A11 Biotechnology
A14 Cell biology
A20 Genetics
A26 Medicine
A32 Pathology
A34 Physiology
73 Investigation and development 2403 Biochemistry
2407.01 Cellular culture
2410.07 Human genetics
2411.15 Vision physiology
2412 Immunology
3201.09 Ophthalmology
3202 Epidemiology
3209.03 Drug test
3213.09 Ocular surgery
3312 Materials technology
Other aspects:
 Training activities:
  • Vision Science doctorate
  • Master of Research in Vision Sciences
  • Master of retina
  
Researchers: other researchers team

_